TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Tcr2 Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Tcr2 Therapeutics Inc market cap is $58.11M.
What is the 52-week high for Tcr2 Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Tcr2 Therapeutics Inc 52 week high is $3.88 as of September 12, 2025.
What is the 52-week low for Tcr2 Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Tcr2 Therapeutics Inc 52 week low is $0.821 as of September 12, 2025.
What is Tcr2 Therapeutics Inc stock price today?
Tcr2 Therapeutics Inc stock price today is $1.51.
What was Tcr2 Therapeutics Inc stock price yesterday?
Tcr2 Therapeutics Inc stock price yesterday was $1.57.
What is the PE ratio of Tcr2 Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Tcr2 Therapeutics Inc’s P/E ratio is -0.35.
What is the Price-to-Book ratio of Tcr2 Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Tcr2 Therapeutics Inc P/B ratio is 0.5732.
What is Tcr2 Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Tcr2 Therapeutics Inc's EBITDA is 0.36.
What is the 50-day moving average of Tcr2 Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Tcr2 Therapeutics Inc 50-day moving average is $1.69.
